Background. Hypertension is one of the leading causes of cardiovascular mortality. Although the pathogenetic process involved is not yet fully understood, the disease involves endothelial damage and inflammation. Calprotectin is an inflammatory marker that rises in parallel with disease activity in conditions such as systemic inflammatory diseases, infection, and atherosclerosis. The purpose of this study was to evaluate inflammation through serum calprotectin levels in newly diagnosed primary hypertension patients. Methods. Forty-nine newly diagnosed hypertensive patients and 38 healthy adults were included in the study. Patients’ office blood pressure values, biochemical findings, and demographic characteristics were recorded. Serum calprotectin levels were measured using ELISA. Parameters affecting serum calprotectin levels and determinants of hypertension were evaluated. Results. Serum calprotectin levels were 242.8 (72.4–524) ng/mL in the control group and 112.6 (67.4–389.8) ng/mL in the hypertensive patient group, the difference being statistically significant (). There was no correlation between serum calprotectin levels and other parameters (blood pressure values, age, gender, serum creatinine, uric acid, and calcium levels) in the hypertensive group. A lower serum calprotectin level was found to be independently related to hypertension (β = −0.009, ). Serum calprotectin at a cutoff level of 128.6 ng/mL differentiated hypertensives from healthy controls with a sensitivity of 69.4% and specificity of 68.4% (AUC = 0.767). Conclusions. The results of this study were the opposite of our hypothesis that a higher calprotectin level may reflect subclinical endothelial damage in newly diagnosed hypertensive patients. Further comparative studies involving patients at different stages of hypertension may contribute to clarifying the relationship between calprotectin and hypertension. We conclude that molecular studies seem essential for understanding the place of calprotectin in hypertension-associated inflammation, a complex process.

中文翻译：

---

血清钙卫蛋白水平作为新诊断高血压患者的炎症标志物

背景。高血压是导致心血管死亡的主要原因之一。尽管所涉及的发病过程尚未完全了解，但该疾病涉及内皮损伤和炎症。钙卫蛋白是一种炎症标志物，在系统性炎症性疾病、感染和动脉粥样硬化等疾病中与疾病活动度同步上升。本研究的目的是通过新诊断的原发性高血压患者的血清钙卫蛋白水平评估炎症。方法. 该研究包括 49 名新诊断的高血压患者和 38 名健康成人。记录患者的诊室血压值、生化结果和人口统计学特征。使用ELISA测量血清钙卫蛋白水平。评估影响血清钙卫蛋白水平和高血压决定因素的参数。结果。对照组血清钙卫蛋白水平为242.8（72.4-524）ng/mL，高血压患者组为112.6（67.4-389.8）ng/mL，差异有统计学意义（）。高血压组血清钙卫蛋白水平与其他参数（血压值、年龄、性别、血清肌酐、尿酸和钙水平）之间没有相关性。发现较低的血清钙卫蛋白水平与高血压独立相关（ β  = -0.009，）。截止水平为 128.6 ng/mL 的血清钙卫蛋白以 69.4% 的敏感性和 68.4% 的特异性（AUC = 0.767）区分高血压与健康对照。结论。这项研究的结果与我们的假设相反，即较高的钙卫蛋白水平可能反映新诊断的高血压患者的亚临床内皮损伤。涉及高血压不同阶段患者的进一步比较研究可能有助于阐明钙卫蛋白与高血压之间的关系。我们得出结论，分子研究似乎对于了解钙卫蛋白在高血压相关炎症中的位置至关重要，这是一个复杂的过程。